Puma Biotechnology, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Puma Biotechnology's 2025 Annual Report details increased NERLYNX product revenue, ongoing alisertib clinical trials, and significant legal challenges impacting international markets and patent validity.
NASDAQ
Puma Biotechnology reports a profitable year in 2024 with $230.5 million in revenue, while actively managing patent litigation and advancing its drug pipeline.
NASDAQ
Puma Biotechnology's 2023 annual report details financial performance, ongoing commercialization of NERLYNX, and development plans for alisertib.